Source comparison
Melanotan-1 vs Other Melanocortin Agonists: Response Comparison
Melanotan-1 (Afamelanotide) High (13× greater than α-MSH) 33 minutes plasma; 8–12 hours receptor occupancy Absolute. Zero melanogenesis without UV 10–14 days with proper UV co-activation Gold standard for photoprotection research; FDA-approved implant formulat
This comparison does not assign a generated winner or score.
- Melanotan-1 (Afamelanotide)
- High (13× greater than α-MSH)
- 33 minutes plasma; 8–12 hours receptor occupancy
- Absolute. Zero melanogenesis without UV
- 10–14 days with proper UV co-activation
- Gold standard for photoprotection research; FDA-approved implant formulation (Scenesse) demonstrates clinical validation; requires disciplined UV timing
- Melanotan-2 (MT-2)
- Moderate (cross-reacts MC3R, MC4R)
- 1–2 hours
- Moderate. Some melanogenesis without UV
- 7–10 days with or without UV
- Broader melanocortin activity creates tanning without UV but introduces unwanted effects (nausea, libido changes, appetite suppression); less predictable response
- α-MSH (endogenous)
- Baseline (1× affinity)
- <10 minutes
- Absolute. Natural tanning mechanism
- 14–21 days seasonal tanning
- Body's natural melanocortin; Melanotan-1 designed as enhanced analog with longer receptor occupancy
- The comparison underscores why Melanotan-1 protocols fail when UV co-activation is omitted. The peptide's design specifically targets MC1R with minimal off-target activity, making it highly selective but entirely UV-dependent. MT-2's broader receptor promiscuity allows some melanogenesis without UV, but researchers using Melanotan-1 expecting similar results misunderstand the fundamental pharmacological difference.